Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.


The response of gastric cancer with peritoneal dissemination to systemic chemotherapy may be negatively affected by poor drug delivery due to the blood-peritoneal barrier. However, S-1 has been reported to be effective. We examined the pharmacokinetics of S-1 in 14 patients who had gastric cancer with peritoneal dissemination. S-1 was given from the morning of the day before surgery to the morning of surgery. Concentrations of 5-fluorouracil (5-FU) and gimeracil (CDHP) were measured in the serum, ascites, disseminated peritoneal nodes, and normal peritoneum. There was a strong correlation between 5-FU and CDHP concentrations in peritoneal tissues. The concentrations of 5-FU and CDHP in the serum were similar to those in ascites. The concentration of 5-FU was significantly higher in disseminated nodes than in the normal peritoneum. After administration of S-1 to gastric cancer patients with peritoneal dissemination, 5-FU and CDHP in the serum linearly pass through the peritoneum and enter the ascites. High concentrations of 5-FU selectively penetrate disseminated peritoneal cells.

6 Figures and Tables

Citations per Year

295 Citations

Semantic Scholar estimates that this publication has 295 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Oshima2006PharmacokineticsOS, title={Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.}, author={Takashi Oshima and Roppei Yamada and Shinsuke Hatori and Chikara Kunisaki and Toshio Imada}, journal={Oncology reports}, year={2006}, volume={16 2}, pages={361-6} }